Doximity Inc. shares fell approximately 21% [6] after the company released its fourth-quarter 2026 financial results on May 13, 2026 [7].
The decline reflects investor concern over a miss in earnings and cautious future guidance, signaling potential headwinds in the pharmaceutical advertising market.
For the fourth quarter of 2026, Doximity reported adjusted earnings per share of 26 cents [1] and GAAP earnings per share of 10 cents [2]. Despite the earnings miss, the company reported a consensus revenue estimate of $0.14 billion [4]. The company also highlighted a record free cash flow of $107 million [3] for the period.
Looking ahead to the next fiscal year, the company provided revenue guidance for FY2027 between $664 million and $676 million [5]. Management said this outlook is due to a combination of softer pharmaceutical spending and a strategic pivot toward AI investment. The company is currently integrating AI tools into its platform to enhance clinician engagement, a move that may pressure short-term margins.
The stock price plunge followed the disclosure of these figures, as the market reacted to the discrepancy between the revenue beat and the overall earnings performance [3, 6]. The company remains focused on its role as a digital hub for healthcare professionals, though it now faces a challenging macroeconomic environment for its primary advertising revenue streams [5].
“Doximity Inc. shares fell approximately 21% after the company released its fourth-quarter 2026 financial results.”
Doximity is navigating a transition period where strong cash reserves are being leveraged to fund AI integration. The stock's volatility suggests that investors are wary of the 'investment year' strategy, particularly as the company's reliance on pharmaceutical advertising makes it vulnerable to budget cuts in the healthcare sector.
